Necrostatin-7
Based on 1 Customer Validation
Necrostatin-7 (Nec-7) is a Necroptosis inhibitor with an EC50 of 10.6 μM. Necrostatin-7 inhibits signal transduction from RANK to NFATc1 without affecting the activation of MAPK or NF-κB. Necrostatin-7 suppresses the expression levels of Acp5, Atp6v0d2, Ctsk and Dcstamp. Necrostatin-7 reduces myocardial infarction size, ameliorates adverse left ventricular remodeling, decreases myocardial wall stress, reduces the amount and length of scar tissue, and improves left ventricular function. Necrostatin-7 exerts cardioprotective effects in a rat model of permanent coronary artery occlusion. Necrostatin-7 can be used in research related to osteolytic bone diseases and myocardial infarction.
For research use only. We do not sell to patients.
- Purity : 99.64%
- CAS No.: 351062-08-3
- Formula: C16H10FN5OS2
- Molecular Weight:371.41
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | EC50 |
10.6 μM
Compound: nec-7
|
Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat cells
Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat cells
|
[PMID: 18768316] |
In Vitro
Necrostatin-7 (0.1-3 μM; 3 days) dose-dependently inhibits M-CSF- and RANKL-induced osteoclast differentiation in primary bone marrow-derived macrophages at concentrations from 0.1 to 3 μM, with near-complete inhibition at 2 μM and 3 μM, without reducing BMM viability[1].
Necrostatin-7 (1-3 μM; 5 days) dose-dependently inhibits osteoclastic bone resorption by primary bone marrow-derived macrophages at concentrations from 1 to 3 μM, with near-complete inhibition at 2 μM and 3 μM after 5 days of treatment[1].
Necrostatin-7 (1-3 μM; 1-3 days) dose-dependently suppresses RANKL-induced expression of osteoclastogenic marker genes (Acp5, Atp6v0d2, Ctsk, Dcstamp) in primary bone marrow-derived macrophages at 1 μM and 3 μM over 1 to 3 days of differentiation[1].
Necrostatin-7 (1-3 μM; 1-3 days) dose-dependently inhibits RANKL-induced NFATc1 autoamplification in primary bone marrow-derived macrophages at 1 μM and 3 μM over 1 to 3 days of differentiation, with near-complete suppression at 3 μM[1].
Necrostatin-7 inhibits TNF-α-induced necroptosis in FADD-deficient human Jurkat T cells with an EC50 of 10.6 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Pretreatment with necrostatin-7 (14.5 mg/kg; i.p.) reduces left ventricular scar tissue and scar length, and lowers plasma N-terminal pro-brain natriuretic peptide levels, indicating improved left ventricular function in rats with permanent coronary occlusion-induced myocardial infarction[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male)[3]
-
Dosage:14.5 mg/kg
-
Administration:i.p.; single dose 1 hour prior to permanent coronary occlusion
-
Result:Reduced serum NT-proBNP level to 0.2 ng/mL.
Reduced myocardial infarct size to 9.0%.
Reduced infarct length to 2.9 mm.
-
Animal Model:strain not specified[4]
-
Dosage:14.5 mg/kg
-
Administration:i.p.; single dose 60 minutes before coronary occlusion
-
Result:Reduced the amount of scar tissue and scar length in the left ventricle.
Decreased plasma levels of N-terminal pro-brain natriuretic peptide.
Chemical Information
-
CAS No. 351062-08-3
-
Appearance Solid
-
Molecular Weight 371.41
-
Formula C16H10FN5OS2
-
Color Light yellow to brown
-
SMILES
O=C1N(C2=NC=CS2)C(S/C1=C\C3=CNN=C3C4=CC=C(F)C=C4)=N
-
Synonyms
Nec-7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 10 mg/mL (26.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fuji H, et al. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation. Biochemical and biophysical research communications. 2018 Sep 05;503(2):544-549. [Content Brief]
[2]. Zheng W, et al. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorganic & medicinal chemistry letters. 2008 Sep 15;18(18):4932-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6924 mL | 13.4622 mL | 26.9244 mL | 67.3111 mL |
| 5 mM | 0.5385 mL | 2.6924 mL | 5.3849 mL | 13.4622 mL | |
| 10 mM | 0.2692 mL | 1.3462 mL | 2.6924 mL | 6.7311 mL | |
| 15 mM | 0.1795 mL | 0.8975 mL | 1.7950 mL | 4.4874 mL | |
| 20 mM | 0.1346 mL | 0.6731 mL | 1.3462 mL | 3.3656 mL | |
| 25 mM | 0.1077 mL | 0.5385 mL | 1.0770 mL | 2.6924 mL |
Keywords
- Necrostatin-7
- 351062-08-3
- Nec-7
- Necrostatin7
- Necrostatin 7
- Nec7
- Nec 7
- Necroptosis
- RANKL/RANK
- myocardial infarction
- primary bone marrow-derived macrophages
- bone resorption
- RANK
- necroptosis
- rat models of permanent coronary occlusion
- NFATc1
- FADD-deficient human Jurkat T cells
- osteoclastogenesis
- RANK-NFATc1 signaling axis
- Inhibitor
- inhibitor
- inhibit